Characteristics and outcomes of 22 consecutive trabeculectomies with or without intraoperative trypan blue
| Case/sex/age | Diagnosis* | Antimetabolite | Pre-op IOP | Pre-op meds | IOP at 2 years | Interventions† | Complications‡ | IOP reduction mmHg (%) |
|---|---|---|---|---|---|---|---|---|
| Diagnosis: OAG, open angle glaucoma; ACG, angle closure glaucoma; UG, uveitis glaucoma; TG, traumatic glaucoma. | ||||||||
| *Case 13: sponges were placed dry and MMC was added via a syringe (see text). | ||||||||
| †Interventions: 5-FU, subconjunctival 5-FU injection; needle, micropuncture of internal bleb walls with 30 gauge needle combined with 5-FU injection; meds, topical glaucoma medications recommenced; CE, cataract extraction. | ||||||||
| ‡Complications: choroidal effusions and wound edge leaks were transient and did not affect vision or require re-operation except for case 2 where wound resuturing was performed. Case 1: hyphaema was associated with oral NSAIDs taken for intercurrent illness. Month 3 wound leak of case 18 (other eye of case 14) was secondary to wound contraction. | ||||||||
| No trypan blue | ||||||||
| 1/M/69 | OAG | 5-FU 50 mg/ml | 32 | 4 | 15 | 5-FU, needle | Hyphaema, day 10 | 17 (53) |
| 2/M/58 | TG | 5-FU 50 mg/ml | 50 | 0 | 18 | 5-FU | Wound edge leak required resuture | 32 (64) |
| 3/M/72 | OAG | MMC 0.4 mg/ml | 44 | 2 | 11 | None | None | 33 (75) |
| 4/M/69 | OAG | 5-FU 50 mg/ml | 38 | 3 | 13 | 5-FU | Choroidal effusion, week 1 | 25 (66) |
| 5/F/69 | UG | 5-FU 50 mg/ml | 29 | 4 | 14 | 5-FU × 4, CE | None | 15 (52) |
| 6/F/57 | OAG | 5-FU 50 mg/ml | 30 | 3 | 11 | 5-FU | None | 19 (63) |
| 7/M/80 | OAG | 5-FU 50 mg/ml | 26 | 3 | 14 | 5-FU | None | 12 (46) |
| 8/F/70 | UG | MMC 0.2 mg/ml | 16 | 4 | 9 | 5-FU | None | 7 (44) |
| 9/M/76 | OAG | MMC 0.2 mg/ml | 22 | 3 | 18 | 5-FU, CE, 2 meds | None | 4 (18) |
| 10/M/64 | ACG | MMC 0.2 mg/ml | 34 | 4 | 5 | 5-FU | None | 29 (85) |
| 11/M/79 | OAG | 5-FU 50 mg/ml | 25 | 4 | 18 | 7 (28) | ||
| Mean | 31.45 | 3.09 | 13.27 | 18 (58) | ||||
| Trypan blue | ||||||||
| 12/F/71 | OAG | 5-FU 45 mg/ml | 20 | 5 | 10 | 5-FU×2 | None | 10 (50) |
| 13*/M/58 | OAG | 5-FU 45 mg/ml | 22 | 3 | 14 | 5-FU | Choroidal effusion, wound edge leak, week 1 | 8 (36) |
| 14/M/55 | ACG | MMC 0.2 mg/ml | 34 | 5 | 10 | None | None | 24 (71) |
| 15/M/80 | OAG | 5-FU 45 mg/ml | 28 | 1 | 8 | 5-FU×3, needle | None | 20 (71) |
| 16/F/85 | UG | MMC 0.2 mg/ml | 27 | 2 | 6 | None | None | 21 (78) |
| 17/M/55 | NVG | MMC 0.4 mg/ml | 36 | 3 | 8 | 5-FU | None | 28 (78) |
| 18/F/80 | OAG | 5-FU 45 mg/ml | 20 | 3 | 14 | 5-FU | None | 6 (30) |
| 19/M/56 | ACG | 5-FU 45 mg/ml | 25 | 2 | 17 | 5-FU needle 2 meds | Wound edge leak, month 3 | 8 (32) |
| 20/M/67 | NTG | 5-FU 45 mg/ml | 8 | 4 | 10 | 5-FU | None | −2 (−25) |
| 21/M/72 | OAG | 5-FU 45 mg/ml | 44 | 4 | 13 | CE | None | 31 (70) |
| 22/M/65 | OAG | 5-FU 45 mg/ml | 42 | 4 | 5 | 5-FU ×2 | Circulating hyphaema, day 1 | 37 (88) |
| Mean | 27.82 | 3.27 | 10.45 | 17 (62) | ||||